Gene-expression profiling in epithelial ovarian cancer

Nature Clinical Practice Oncology

Volumn 5, Issue 10, 2008, Pages 577-587

  Konstantinopoulos, Panagiotis A ^a   Spentzos, Dimitrios ^a   Cannistra, Stephen A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; COMPLEMENTARY DNA; CREATINE KINASE BB; EPIDIDYMAL SECRETORY PROTEIN; EPIDIDYMAL SECRETORY PROTEIN 4; EPITHELIAL CELL ADHESION MOLECULE; KALLIKREIN; KALLIKREIN 10; MATRILYSIN; OSTEOPONTIN; PACLITAXEL; PLATINUM COMPLEX; PROSTASIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA MICROARRAY; DRUG RESPONSE; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; LAPAROSCOPY; MOLECULAR DYNAMICS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 53749083670     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1178     Document Type: Review

References (88)

1. Jemal A et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66
2. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529
3. McGuire WP et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
4. Ozols RF et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200
5. Bristow RE et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20: 1248-1259
6. Thigpen T et al. (1993) Age as a prognostic factor in ovarian carcinoma: The Gynecologic Oncology Group experience.Cancer 71 606-614
7. Baekelandt M et al. (1999) Clinical significance of apoptosis-related factors p53, Mdm2, and BcI-2 in advanced ovarian cancer. J Clin Oncol 17: 2061
8. Kupryjanczyk J et al. (2003) Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 88: 848-854
9. Nielsen JS et al. (2004) Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 14: 1086-1096
10. van Dam PA et al. (1994) Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 47 914-919
11. Golub TR (2001) Genome-wide views of cancer. N Engl J Med 344 601-602
12. Elvidge G (2006) Microarray expression technology: From start to finish. Pharmacogenomics 7: 123-134
13. Tefferi A et al. (2002) Primer on medical genomics. Part III: microarray experiments and data analysis. Mayo Clin Proc 77: 927-940
14. Simon R (2005) Roadmap, for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23: 7332-7341
15. Ntzani EE and Ioannidis JP (2003) Predictive ability of DNA microarrays for cancer outcomes and correlates: An empirical assessment. Lancet 362: 1439-1444
16. Quackenbush J (2007) Extracting biology from high-dimensional biological data. J Exp Biol 210: 1507-1517
17. Ramaswamy S and Golub TR (2002) DNA microarrays in clinical oncology. J Clin Oncol 20: 1932-1941
18. Fan C et al. (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355: 560-569
19. Berchuck A et al. (2004) Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 190: 910-925
20. Berchuck A et al. (2005) Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11: 3686-3696
21. Hartmann LC et al. (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11: 2149-2155
22. Lancaster JM et al. (2004) Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 11: 51-59
23. Spentzos D et al. (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22: 4700-4710
24. Rancano C et al. (1994) Genomic structure and subcellular localization of MAL, a human T-cell-specific proteolipid protein. J Biol Chem 269: 8159-8164
25. Tracey L et al. (2002) Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol 161: 1825-1837
26. Hu YL et al. (2003) Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst 95: 733-740
27. Sotiriou C and Piccart MJ (2007) Taking gene-expression profiling to the clinic: When will molecular signatures become relevant to patient care? Nat Rev Cancer 7: 545-553
28. Quackenbush J (2006) Microarray analysis and tumor classification. N Engl J Med 354: 2463-2472
29. Arts HJ et al. (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5: 2798-2805
30. Reles A et al. (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7: 2984-2997
31. van der Zee AG et al. (1995) Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70-78
32. Dressman HK et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25: 517-525
33. Helleman J et al. (2006) Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118: 1963-1971
34. Selvanayagam ZE et al. (2004) Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet 154: 63-66
35. Spentzos D et al. (2005) Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23: 7911-7918
36. Strobel T et al. (1998) BAX expression is associated with enhanced intracellular accumulation of paclitaxel: A novel role for BAX during chemotherapy-induced cell death. Cancer Res 58: 4776-4781
37. Strobel T et al. (1996) BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 93 14094-14099
38. Bild AH et al. (2006) Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 6: 735-741
39. Bild AH et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357
40. Potti A et al. (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12: 1294-1300
41. Bani MR et al. (2004) Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 3 111-121
42. Goto T et al. (2006) Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol Rep 15: 1265-1271
43. Li J et al. (2007) Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene 26: 2860-2872
44. Macleod K et al. (2005) Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 65 6789-6800
45. Roberts D et al. (2005) Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92: 1149-1158
46. Kim JS et al. (2005) The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther 4: 487-493
47. Khabele D et al. (2004) Tumor necrosis factor-alpha related gene response to epothilone B in ovarian cancer. Gynecol Oncol 93 19-26
48. Clarke PA et al. (2004) Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo. Br J Cancer 91: 1614-1623
49. Cheng TC et al. (2006) Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 58: 384-395
50. Sakamoto M et al. (2001) Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 14: 305-315
51. Samimi G et al. (2005) cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol 55: 1-11
52. Jazaeri AA et al. (2005) Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11: 6300-6310
53. Hogg R and Friedlander M (2004) Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 22: 1315-1327
54. Meinhold-Heerlein I et al. (2007) An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res 13: 458-466
55. Mok SC et al. (2001) Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology. J Natl Cancer Inst 93: 1458-1464
56. Kim JH et al. (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287: 1671-1679
57. Wong KK et al. (2001) Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30: 670-675
58. Schummer M et al. (1999) Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238: 375-385
59. Kim JH et al. (2003) Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9: 4782-4791
60. Huddleston HG et al. (2005) Clinical applications of microarray technology: Creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 96: 77-83
61. Shvartsman HS et al. (2003) Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90: 44-50
62. Zorn KK et al. (2003) Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 9: 4811-4818
63. Schwartz DR et al. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729
64. Zorn KK et al. (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11: 6422-6430
65. Motzer RJ and Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24: 5601-5608
66. Bonome T et al. (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65: 10602-10612
67. Meinhold-Heerlein I et al. (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24: 1053-1065
68. Singer G et al. (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160: 1223-1228
69. Dupuy A and Simon RM (2007) Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99: 147-157
70. Shi L et al. (2006) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24: 1151-1161
71. Brazma A et al. (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365-371
72. Paik S et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 817-2826
73. Lamb J et al. (2006) The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935
74. Funaoka K et al. (1997) Activation of the p21 (Waf1/Cip1) promoter by the ets oncogene family transcription factor E1AF. Biochem Biophys Res Commun 236: 79-82
75. Han JY et al. (2006) The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 54: 227-234
76. Taniguchi T et al. (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9: 568-574
77. Liu N et al. (1997) The human XRCC9 gene corrects chromosomal instability and mutagen sensitivities in CHO UV40 cells. Proc Natl Acad Sci USA 94: 9232-9237
78. Li X et al. (2005) Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci 62: 894-904
79. Sun CL and Chao CC (2005) Cross-resistance to death ligand-induced apoptosis in cisplatin-selected HeLa cells associated with overexpression of DDB2 and subsequent induction of cFLIP. Mol Pharmacol 67: 1307-1314
80. Albertella MR et al. (2005) A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res 65 9799-9806
81. Kepp O et al. (2007) Bak and Bax are non-redundant during infection- and DNA damage-induced apoptosis. EMBO J 26: 825-834
82. Shi R et al. (2007) Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol Cancer Ther 6: 1338-1347
83. Aoyagi Y et al. (2005) A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity. Cancer Sci 96: 614-619
84. Vlachos P et al. (2007) The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ 14: 1497-1507
85. Villedieu M et al. (2007) Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: Link with ERK activation and modulation of p21WAF1/CIP1, BcI-2 and BcI-xL expression. Gynecol Oncol 105: 373-384
86. Kerley-Hamilton JS et al. (2005) A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene 24: 6090-6100
87. Shen DW et al. (2006) Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance. Mol Pharmacol 69: 1383-1388
88. Johansson K et al. (2007) Microsomal glutathione transferase 1 in anticancer drug resistance. Carcinogenesis 28: 465-470